From: Metabolic phenotypes in primary unknown metastatic carcinoma
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | |||
---|---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | ||
Glut-1 (T) | 0.101 | ||||
Negative | 34 | 13 | 74 (49–98) | ||
Positive | 25 | 5 | 55 (42–68) | ||
Glut-1 (S) | N/A | N/A | |||
Negative | 59 | 18 | 84 (66–102) | ||
Positive | 0 | 0 | N/A | ||
CAIX (T) | 0.272 | ||||
Negative | 51 | 17 | 82 (63–101) | ||
Positive | 8 | 1 | 54 (30–79) | ||
CAIX (S) | N/A | ||||
Negative | 57 | 18 | N/A | ||
Positive | 2 | 0 | N/A | ||
MCT4 (T) | 0.759 | ||||
Negative | 19 | 5 | 87 (59–115) | ||
Positive | 40 | 13 | 80 (57–103) | ||
MCT4 (S) | 0.631 | ||||
Negative | 34 | 9 | 94 (73–115) | ||
Positive | 25 | 9 | 43 (29–57) | ||
GLS1 (T) | 0.139 | ||||
Negative | 39 | 10 | 49 (38–60) | ||
Positive | 20 | 8 | 73 (42–103) | ||
GLS1 (S) | 0.721 | ||||
Negative | 50 | 15 | 84 (65–104) | ||
Positive | 9 | 3 | 46 (22–69) | ||
GDH (T) | 1.000 | ||||
Negative | 7 | 2 | 28 (14–39) | ||
Positive | 52 | 16 | 85 (66–104) | ||
GDH (S) | 0.786 | ||||
Negative | 44 | 13 | 90 (72–109) | ||
Positive | 15 | 5 | 40 (19–60) | ||
ASCT2 (T) | 0.506 | ||||
Negative | 38 | 13 | 78 (54–101) | ||
Positive | 21 | 5 | 36 (27–45) | ||
ASCT2 (S) | 0.227 | ||||
Negative | 56 | 16 | 87 (68–105) | ||
Positive | 3 | 2 | 16 (1–32) | ||
ATP synthase (T) | 0.653 | ||||
Negative | 2 | 1 | 10 (10–10) | ||
Positive | 57 | 17 | 85 (67–104) | ||
ATP synthase (S) | 0.535 | ||||
Negative | 48 | 14 | 88 (68–107) | ||
Positive | 11 | 4 | 23 (12–34) | ||
SDHA (T) | 0.906 | ||||
Negative | 3 | 1 | 28 (13–43) | ||
Positive | 56 | 17 | 84 (66–103) | ||
SDHA (S) | 0.588 | ||||
Negative | 44 | 13 | 90 (70–109) | ||
Positive | 15 | 5 | 37 (15–58) | ||
SDHB (T) | 0.166 | ||||
Negative | 23 | 5 | 86 (56–115) | ||
Positive | 36 | 13 | 79 (57–102) | ||
SDHB (S) | 0.923 | ||||
Negative | 51 | 16 | 84 (65–103) | ||
Positive | 8 | 2 | 27 (16–37) |